Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-05-11Clinical Trial Update: A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression [Phase 2]
Phase 2 home-based trial of BI 1358894 for depression was terminated; results posted in 2023.
-
FDA approval · 2023-05-11FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for quetiapine fumarate from Aurobindo Pharma Limited, enabling generic production under an Abbrevia…
-
FDA approval · 2023-05-11FDA Approved: QUETIAPINE — Supplemental Application (Ascend Laboratories, LLC)
The FDA granted a supplemental approval for Quetiapine (generic) from Ascend Laboratories, LLC, approving an additional application for this…
-
FDA approval · 2023-05-10FDA Approved: REXULTI — Supplemental Application (Otsuka America Pharmaceutical, Inc.)
The FDA approved a supplemental application for Rexulti (brexpiprazole) submitted by Otsuka America Pharmaceutical, Inc., resulting in chang…
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: Antidepressants Trial in Parkinson's Disease [Phase 3]
Phase 3 clinical trial investigating antidepressants for depression in Parkinson's disease has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: Accelerated TMS to a Novel Brain Target in MDD and PTSD [NA]
Clinical trial update on accelerated TMS targeting a novel brain region for major depressive disorder and post-traumatic stress disorder; st…
-
FDA approval · 2023-05-02FDA Approved: DULOXETINE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application from Actavis Pharma, Inc. for duloxetine under ANDA 090776, granting approval for a supplemental cha…
-
FDA approval · 2023-05-02FDA Approved: DULOXETINE — Supplemental Application (Solco Healthcare US, LLC)
The FDA approved a supplemental application for duloxetine submitted by Solco Healthcare US, LLC (ANDA206653), authorizing a change related …
-
FDA approval · 2023-05-01FDA Approved: IMIPRAMINE HYDROCHLORIDE — Supplemental Application (Strides Pharma Science Limited)
The FDA approved a supplemental application for imipramine hydrochloride from Strides Pharma Science Limited, enabling continued marketing o…
-
FDA approval · 2023-05-01FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Par Health USA, LLC)
FDA announces a supplemental approval for a generic fixed-dose combination of olanzapine and fluoxetine by Par Health USA, LLC under ANDA 07…
-
FDA approval · 2023-05-01FDA Approved: IMIPRAMINE HYDROCHLORIDE — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for imipramine hydrochloride by Strides Pharma Science Limited, a generic antidepressant.
-
FDA approval · 2023-05-01FDA Approved: AMITRIPTYLINE HYDROCHLORIDE — Original Application (Advagen Pharma Ltd)
FDA approved Advagen Pharma Ltd's original application for Amitriptyline Hydrochloride (generic) under ANDA, authorizing its marketing in th…
-
CLINICAL_TRIALS trial_result · 2023-04-26Clinical Trial Update: Self System Therapy and Chronic Low Back Pain Trial [Phase 4]
Phase 4 clinical trial update for Self System Therapy in chronic low back pain and depression has completed recruitment.
-
CLINICAL_TRIALS trial_result · 2023-04-25Clinical Trial Update: Light Therapy for Depression in Adolescent Outpatients [Phase 4]
A Phase 4 trial update on light therapy for depression in adolescent outpatients completed.
-
CLINICAL_TRIALS withdrawal · 2023-04-24Clinical Trial Update: Neurobiology of Treatment Responses in MDD [Phase 3]
A Phase 3 clinical trial for major depressive disorder has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2023-04-24Clinical Trial Update: MBCT Delivered Via Group Videoconferencing for ACS Syndrome Patients With Depressive Symptoms [NA]
Clinical trial update on MBCT delivered via group videoconferencing for patients with acute coronary syndrome and depressive symptoms; statu…
-
CLINICAL_TRIALS trial_result · 2023-04-24Clinical Trial Update: Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy [Phase 2, Phase 3]
Phase 2/3 trial update on ketamine for severe adolescent major depressive disorder; study terminated with posted results in 2023.
-
FDA approval · 2023-04-20FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Ingenus Pharmaceuticals, LLC)
FDA approved a supplemental application for quetiapine fumarate from Ingenus Pharmaceuticals, LLC, marking an additional approval/modificati…
-
FDA approval · 2023-04-19FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for quetiapine fumarate from Aurobindo Pharma Limited, authorizing a generic version under an ANDA.
-
FDA approval · 2023-04-19FDA Approved: QUETIAPINE — Supplemental Application (Solco Healthcare U.S., LLC)
FDA approved a supplemental application for quetiapine from Solco Healthcare U.S., LLC to authorize a generic version of the drug for the U.…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression [Phase 4]
Phase 4 clinical trial evaluating immunomarkers to guide pharmacotherapy in depression was terminated; results posted previously.
-
FDA approval · 2023-04-12FDA Approved: VENLAFAXINE — Original Application (Ajanta Pharma USA Inc.)
FDA approves Ajanta Pharma USA Inc.'s original generic application for venlafaxine. The approval covers generic venlafaxine for the treatmen…
-
FDA approval · 2023-04-06FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for escitalopram oxalate from Quallent Pharmaceuticals Health LLC, authorizing a generic version of …
-
CLINICAL_TRIALS trial_result · 2023-04-06Clinical Trial Update: The Omega-3 Fatty Acid Paediatric Depression Trial [Phase 3]
Phase 3 clinical trial update for an omega-3 fatty acid in paediatric depression has completed recruitment.
-
CLINICAL_TRIALS trial_result · 2023-04-05Clinical Trial Update: Neuroimaging Guided and Robot-assisted rTMS for Suicidal Ideation of Depression [Phase 2]
Phase 2 clinical trial update evaluating neuroimaging guided and robot-assisted repetitive transcranial magnetic stimulation (rTMS) for suic…